The administration, as well as HHS, publicly praised Marty Makary’s leadership despite persistent upheaval at the agency.

Sarepta stock crashed Tuesday after the biotech company said two of its muscular dystrophy drugs failed confirmatory tests.

Shares of Sarepta Therapeutics ($SRPT) plunged after the company reported disappointing results from a key trial of its Duchenne muscular ...

We’re also continuing to track the fallout from all the recent FDA controversies.

Sarepta Therapeutics, Inc. faces revenue decline, trial setbacks, and FDA decisions. Click for SRPT risks, outlook, and if ...

The firm's stock tumbled on the news, dropping from $24.45 per share at market close Monday to $15.24 per share when the market opened Tuesday.

Major U.S. equities indexes were lower at midday Tuesday, with Palantir Technologies leading tech stocks lower.

Sarepta's Duchenne trial missed its main goal but showed trends favoring treatment; Q3 earnings topped estimates amid ...

Sarepta Pharmaceuticals Inc (NASDAQ: SRPT) stock is plummeting down, down 31.4% at $16.77 at last glance. Though the biotech ...

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock fell sharply Tuesday following disappointing results from a key clinical trial and ongoing concerns about its drug pipeline. However, "Pharma Bro" ...

Sarepta Therapeutics shares plunged 37% after two Duchenne muscular dystrophy drugs failed a key trial, raising regulatory ...

Amid historic advances in cell-based therapies and precision medicine, biotech’s biggest challenge isn’t scientific, it’s ...